Literature DB >> 16238823

The natural history of meningococcal carriage and disease.

C L Trotter1, N J Gay, W J Edmunds.   

Abstract

The prevalence of Neisseria meningitidis carriage is highest in teenagers and lowest in young children. In contrast, invasive meningococcal disease is most common in young children with a smaller secondary peak in teenagers. Data on carriage and disease were analysed to quantify the risks of infection and disease by age and serogroup. The forces of infection for serogroups B, C, other meningococci and Neisseria lactamica were modelled together with the risk of disease given infection for serogroups B and C, using maximum likelihood to fit the models to the available data. The risk of meningococcal disease given infection declines steeply through childhood and is higher for serogroup C than for serogroup B. The secondary peak in disease in teenagers appears to be explained mostly by increased transmission although there is a suggestion that other factors may also contribute. These analyses provide important insights and may be used to guide further data collection and modelling studies.

Entities:  

Mesh:

Year:  2005        PMID: 16238823      PMCID: PMC2870423          DOI: 10.1017/S0950268805005339

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  22 in total

1.  Back-calculating the age-specific incidence of recurrent subclinical Haemophilus influenzae type b infection.

Authors:  K Auranen
Journal:  Stat Med       Date:  2000-02-15       Impact factor: 2.373

2.  Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination.

Authors:  Martin C J Maiden; James M Stuart
Journal:  Lancet       Date:  2002-05-25       Impact factor: 79.321

3.  Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis.

Authors:  Mary E Ramsay; Nick J Andrews; Caroline L Trotter; Edward B Kaczmarski; Elizabeth Miller
Journal:  BMJ       Date:  2003-02-15

4.  Methods for estimating the duration of bacterial carriage.

Authors:  P De Wals; A Bouckaert
Journal:  Int J Epidemiol       Date:  1985-12       Impact factor: 7.196

5.  Fatal outcome from meningococcal disease--an association with meningococcal phenotype but not with reduced susceptibility to benzylpenicillin.

Authors:  Caroline L Trotter; Andrew J Fox; Mary E Ramsay; Francesca Sadler; Stephen J Gray; Richard Mallard; Edward B Kaczmarski
Journal:  J Med Microbiol       Date:  2002-10       Impact factor: 2.472

6.  Mathematical modelling of infection and disease due to Neisseria meningitidis and Neisseria lactamica.

Authors:  P G Coen; K Cartwright; J Stuart
Journal:  Int J Epidemiol       Date:  2000-02       Impact factor: 7.196

7.  Seven-week interval between acquisition of a meningococcus and the onset of invasive disease. A case report.

Authors:  K R Neal; J S Nguyen-van-Tam; R C Slack; E B Kaczmarski; A White; D A Ala'Aldeen
Journal:  Epidemiol Infect       Date:  1999-12       Impact factor: 2.451

8.  Immunological investigations of meningococcal disease. III. Brevity of group C acquisition prior to disease occurrence.

Authors:  E A Edwards; L F Devine; G H Sengbusch; H W Ward
Journal:  Scand J Infect Dis       Date:  1977

9.  Carriage of Neisseria meningitidis and Neisseria lactamica in infants and children.

Authors:  R Gold; I Goldschneider; M L Lepow; T F Draper; M Randolph
Journal:  J Infect Dis       Date:  1978-02       Impact factor: 5.226

10.  Human immunity to the meningococcus. I. The role of humoral antibodies.

Authors:  I Goldschneider; E C Gotschlich; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

View more
  37 in total

Review 1.  Serogroup A meningococcal conjugate vaccines: building sustainable and equitable vaccine strategies.

Authors:  Amy C Sherman; David S Stephens
Journal:  Expert Rev Vaccines       Date:  2020-04-29       Impact factor: 5.217

2.  Meningococcal Carriage Evaluation in Response to a Serogroup B Meningococcal Disease Outbreak and Mass Vaccination Campaign at a College-Rhode Island, 2015-2016.

Authors:  Heidi M Soeters; Melissa Whaley; Nicole Alexander-Scott; Koren V Kanadanian; Jessica R MacNeil; Stacey W Martin; Lucy A McNamara; Kenneth Sicard; Cynthia Vanner; Jeni Vuong; Xin Wang; Utpala Bandy; Manisha Patel
Journal:  Clin Infect Dis       Date:  2017-04-15       Impact factor: 9.079

3.  A critical threshold of meningococcal factor H binding protein expression is required for increased breadth of protective antibodies elicited by native outer membrane vesicle vaccines.

Authors:  Oliver Koeberling; Isabel Delany; Dan M Granoff
Journal:  Clin Vaccine Immunol       Date:  2011-03-02

Review 4.  Bexsero® chronicle.

Authors:  George Vernikos; Duccio Medini
Journal:  Pathog Glob Health       Date:  2014-10       Impact factor: 2.894

5.  Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity.

Authors:  Helen Campbell; Nick Andrews; Ray Borrow; Caroline Trotter; Elizabeth Miller
Journal:  Clin Vaccine Immunol       Date:  2010-03-10

6.  Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera.

Authors:  Dan M Granoff; Jo Anne Welsch; Sanjay Ram
Journal:  Infect Immun       Date:  2008-12-01       Impact factor: 3.441

7.  Evidence of a functional B-cell immunodeficiency in adults who experience serogroup C meningococcal disease.

Authors:  Rachel A Foster; Jennifer Carlring; Michael W McKendrick; Andrew Lees; Ray Borrow; Robert C Read; Andrew W Heath
Journal:  Clin Vaccine Immunol       Date:  2009-03-11

8.  Seroprevalence of bactericidal and anti-outer membrane vesicle antibodies to Neisseria meningitidis group B in England.

Authors:  Caroline Trotter; Jamie Findlow; Paul Balmer; Ann Holland; Rita Barchha; Nick Hamer; Nick Andrews; Elizabeth Miller; Ray Borrow
Journal:  Clin Vaccine Immunol       Date:  2007-05-09

Review 9.  Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs.

Authors:  Caroline L Trotter; Martin C J Maiden
Journal:  Expert Rev Vaccines       Date:  2009-07       Impact factor: 5.217

10.  CD14 C-159T and toll-like receptor 4 Asp299Gly polymorphisms in surviving meningococcal disease patients.

Authors:  Ariane Biebl; Axel Muendlein; Zhyrgal Kazakbaeva; Sigrid Heuberger; Gudrun Sonderegger; Heinz Drexel; Susanne Lau; Renate Nickel; Michael Kabesch; Burkhard Simma
Journal:  PLoS One       Date:  2009-10-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.